GaDia is Swiss startup developing an innovative, patented rapid in vitro diagnostic (IVD) test to detect nosocomial diseases. More specifically we develop new rapid Point-Of-Care (POC) diagnostic tests to differentiate healthcare-acquired fungal infections from other causes of infections.
Find locations served, office locations
- Business Type:
- Industry Type:
- Medical Monitoring
- Market Focus:
- Nationally (across the country)
- Year Founded:
About GaDia SA
GaDia was founded in 2019 and is located in the Heart of Swiss Health Valley in the startup incubator BioArk in Monthey (Switzerland).
The project was initiated by Percevent J Ducrest (MSc), graduated from University of Applied Sciences Western Switzerland (HES-SO) and Bern University of Applied Sciences (BFH). Percevent received a grant from The Ark Foundation in 2018 to continue the assay development. He has conducted several R&D projects for external companies in the field of in vitro diagnostic tests and microbiology and is the inventor of 2 rapid diagnostic tests. In 2019, 2 C-level partners holding Bachelor and Master degrees in Finance and Management joined GaDia, bringing a wide expertise in corporate management positions in pharmaceutical and medical device businesses in Switzerland and abroad.
Bring Complex Diagnostics to Patient’s Bed
When time matters! GaDia reinvents the diagnostic of life-threatening diseases to quickly provide the right information to healthcare professionals.